Patients' experiences of niacin-induced flushing in clinical practice: A structured telephone interview

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 130-140

  Kamal Bahl, Sachin ^a   Watson, Douglas J ^a   Ambegaonkar, Baishali M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cardiovascular disease; discontinuation; flushing; high density lipoprotein cholesterol; niacin

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINIC ACID;

ADULT; ARTICLE; CLINICAL PRACTICE; COLLEGE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG USE; DRUG WITHDRAWAL; EDUCATION; EXPERIENCE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PHYSICIAN; PREDICTOR VARIABLE; PROPHYLAXIS; RATING SCALE; RECOMMENDED DRUG DOSE; RISK; SIDE EFFECT; SKIN MANIFESTATION; SKIN PRURITUS; SKIN REDNESS; SKIN TINGLING; SKIN WARMING; SLEEP DISORDER; STOMACH DISEASE; STOMACH PAIN; STRUCTURED INTERVIEW; TELEPHONE; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; ASPIRIN; DATA COLLECTION; FEMALE; FLUSHING; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIACIN; PATIENT EDUCATION AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 60349085760     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.011     Document Type: Article

References (26)

1. Birjmohun R.S., Hutten B.A., Kastelem J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol. 45 (2005) 185-197
2. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 164 (2004) 697-705
3. Goldberg A.C. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol. 94 (2004) 121-124
4. Birjmohun R.S., Hutten B.A., Kastelem J.J., and Stroes E.S. Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice. Neth J Med. 62 (2004) 229-234
5. Whelan A.M., Price S.O., Fowler S.F., and Hamer B.L. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 34 (1992) 165-168
6. Jungnickel P.W., Maloley P.A., VanderTum E.L., et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Cen Intern Med. 12 (1997) 591-596
7. Dunn R.T., Ford M.A., Rindone J.P., and Kwiecinski F.A. Low-dose aspirin and Ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 2 (1995) 478-480
8. Cefah E.A., Simmons P.D., Stanek E.J., et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther. 45 (2007) 78-88
9. Nag S.S., Daniel G.W., Bullano M.F., et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 13 (2007) 652-663
10. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 241 (1997) 317-325
11. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol. 82 (1998) 74U-81U discussion
12. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol. 82 (1998) 85U-86U
13. Norquist J.M., Watson D.J., Yu Q., et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 23 (2007) 1549-1560
14. In: Montgomery D.C. (Ed). Design and Analysis of Experiments. 5th ed. (2001), John Wiley, New York, NY
15. In: Hosmer D.W., and Lemeshow S. (Eds). Applied Logistic Regression. 2nd ed. (2000), John Wiley, New York, NY
16. Deyo R.A., Cherkm D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45 (1992) 613-619
17. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. published correction appears in. Circulation 110 (2004) 3615
18. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
19. Guyton J.R., Goldberg A.C., Kreisberg R.A., et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 82 (1998) 737-743
20. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): Efficacy, tolerabihty, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 29U-34U discussion
21. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): Efficacy, tolerabihty, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 39U-41U
22. Kane M.P., Hamilton R.A., Addesse E., et al. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy. 21 (2001) 1473-1478
23. Hiatt J.G., Shamsie S.G., and Schectman G. Discontinuation rates of cholesterol-lowering medications: Implications for primary care. Am J Manag Care. 5 (1999) 437-444
24. Kamal-Bahl S.J., Burke T., Watson D., and Wentworth C. Discontinuation of lipid modifying drugs among commercially insured US patients in recent clinical practice. Am J Cardiol. 99 (2007) 530-534
25. Birjmohun R.S., Kastelein J.J., Polder-mans D., et al. Safety and tolerabihty of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin. 23 (2007) 1707-1713
26. Rubenfire M., and the Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol. 94 (2004) 306-311